Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India and China Could Be On The Brink Of A Biosimilars Takeoff, Says One Biotech CEO

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - Asia's giants - India and China - could see a Big Bang-like explosion of biotech- and biosimilar-focused start-ups given the right conditions over the next decade, including an infusion of capital from the West, according to the head of an Indian biopharmaceutical firm

You may also be interested in...



Divi's Gears Up For A Biosimilars Play, Move Comes At The Back Of Demand From Existing Clients

HYDERABAD, India - Years of relationship with large multinational companies has prompted Divi's Labs - one of India's largest contract manufacturers for pharmaceutical raw materials or bulk drugs - to explore a presence in the biosimilars manufacturing space

Divi's Gears Up For A Biosimilars Play, Move Comes At The Back Of Demand From Existing Clients

HYDERABAD, India - Years of relationship with large multinational companies has prompted Divi's Labs - one of India's largest contract manufacturers for pharmaceutical raw materials or bulk drugs - to explore a presence in the biosimilars manufacturing space

Sanofi-Aventis Sees India's Shantha As Global Hub For Its Biotech Plans

MUMBAI - French drug maker Sanofi-Aventis sees Shantha Biotech - its latest Indian acquisition - as a hub to further its global biotech ambitions but may not rush to buy more companies in India

Latest News
See All
UsernamePublicRestriction

Register

SC074387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel